omadacycline (nuzyra) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Omadacycline is a tetracyclin-derivative antibiotic, originated in Tufts University, and later co-developed by Merck and Paratek Pharmaceuticals. The drug was approved for treatment of community-acquired pneumonia, and for treatment of acute bacterial skin and skin structure infections. Omadacycline tosylate is available as tablets and in injectable form.   NCATS

  • SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(CNCC(C)(C)C)c(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)N(C)C
  • Mol. Mass: 556.66
  • ALogP: 1.32
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$139.8350 - $270.2910
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

7-dimethylamino-9-(2,2-dimethylpropyl)aminomethylcycline | amadacyclin | amadacycline | omadacycline | omadacycline tosylate | ptk0796 | ptk 0796 | ptk-0796


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue